卵巢癌治疗前沿:PARP抑制剂最新进展
本文综述了四项III期试验(SOLO-1、PAOLA-1/ENGOT-OV25、PRIMA/ENGOT-OV26和VELIA/GOG-3005),这些试验评估了PARP抑制剂(奥拉帕利、尼拉帕利或维利帕利)作为新诊断卵巢癌的治疗和/或维持治疗,均显示无进展生存期显著改善。试验设计、患者选择和主要分析人群的差异影响结论解读,总生存数据待成熟,长期安全性经验有限。PARP抑制剂在新诊断卵巢癌管理中起关键作用,并将影响后续治疗选择。
要点
- 四项III期试验显示PARP抑制剂为新诊断卵巢癌带来显著无进展生存期获益。
- 试验设计(治疗/维持、单药/联合、是否联合贝伐珠单抗)和患者选择影响结论。
- 总生存数据尚未成熟,长期安全性经验有限。
核心结论
- PARP抑制剂在新诊断卵巢癌管理中起关键作用,并将影响后续治疗选择。
研究设计与样本
- 综述四项评估PARP抑制剂作为新诊断卵巢癌治疗和/或维持治疗的III期试验(SOLO-1、PAOLA-1/ENGOT-OV25、PRIMA/ENGOT-OV26和VELIA/GOG-3005)。
主要发现
- 四项III期试验显示PARP抑制剂(奥拉帕利、尼拉帕利或维利帕利)为新诊断卵巢癌带来显著无进展生存期改善。
- 试验设计(治疗和/或维持设置;单药或联合;联合或不联合贝伐珠单抗)、患者选择(手术结局、生物标志物资格、预后)和主要分析人群(意向治疗、BRCA突变或同源重组缺陷阳性)的差异影响可得出的结论。
- 总生存数据待成熟,长期安全性经验有限。
临床怎么用
- PARP抑制剂应纳入新诊断卵巢癌的治疗策略,并考虑对后续治疗选择的影响。
- 需根据试验设计、患者选择和生物标志物状态(如BRCA突变、同源重组缺陷)个体化选择PARP抑制剂方案。
局限性
- 总生存数据尚未成熟。
- 长期安全性经验有限。
- 试验设计、患者选择和主要分析人群的差异限制了结论的直接比较和推广。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recurrent ovarian cancer, poly(ADP-ribose) polymerase (PARP)-inhibiting agents have transformed the treatment of platinum-sensitive disease. New data support use of PARP inhibitors earlier in the treatment algorithm. DESIGN: We review results from recent phase III trials evaluating PARP inhibitors as treatment and/or maintenance therapy for patients with newly diagnosed ovarian cancer. We discuss the efficacy and safety of these agents in the all-comer and biomarker-selected populations studied in clinical trials, and compare the strengths and limitations of the various trial designs. We also consider priorities for future research, with a particular focus on patient selection and future regimens for populations with high unmet need. RESULTS: Four phase III trials (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) demonstrated remarkable improvements in progression-free survival with PARP inhibitor therapy (olaparib, niraparib or veliparib) for newly diagnosed ovarian cancer. Differences in trial design (treatment and/or maintenance setting; single agent or combination; bevacizumab or no bevacizumab), patient selection (surgical outcome, biomarker eligibility, prognosis) and primary analysis population (intention-to-treat, BRCA mutated or homologous recombination deficiency positive) affect the conclusions that can be drawn from these trials. Overall survival data are pending and there is limited experience regarding long-term safety. CONCLUSIONS: PARP inhibitors play a pivotal role in the management of newly diagnosed ovarian cancer, which will affect subsequent treatment choices. Refinement of testing for patient selection and identification of regimens to treat populations that appear to benefit less from PARP inhibitors are a priority.
引用
- Mirza MR, Coleman RL, González-Martín A, et al. The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 2020. PMID: 32569725. doi:10.1016/j.annonc.2020.06.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。